Walleye Capital
CYTK icon

Walleye Capital’s Cytokinetics CYTK Stock Holding History

Walleye Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$672K Sell
10,200
-7,400
-42% -$470K ﹤0.01% 2425
2025
Q4 		$1.12M Sell
17,600
-27,700
-61% -$1.72M ﹤0.01% 2343
2025
Q3 		$2.49M Sell
45,300
-74,200
-62% -$3.06M 0.01% 1413
2025
Q2 		$3.95M Buy
119,500
+118,800
+16,971% +$4.13M 0.02% 1027
2025
Q1 		$28.1K Buy
+700
New +$32.2K ﹤0.01% 3965
2024
Q3 		– Sell
-2,400
Closed -$130K – 5392
2024
Q2 		$130K Sell
2,400
-22,200
-90% -$1.34M ﹤0.01% 4578
2024
Q1 		$1.72M Buy
24,600
+6,300
+34% +$487K ﹤0.01% 2105
2023
Q4 		$1.53M Buy
18,300
+9,300
+103% +$337K ﹤0.01% 1999
2023
Q3 		$265K Sell
9,000
-25,300
-74% -$843K ﹤0.01% 3339
2023
Q2 		$1.12M Buy
+34,300
New +$1.27M ﹤0.01% 1759
2023
Q1 		– Sell
-4,700
Closed -$215K – 4006
2022
Q4 		$215K Buy
4,700
+3,800
+422% +$164K ﹤0.01% 1991
2022
Q3 		$44K Buy
+900
New +$43.3K ﹤0.01% 2609
2020
Q2 		– Sell
-1,000
Closed -$12K – 676
2020
Q1 		$12K Buy
+1,000
New +$12.8K ﹤0.01% 779

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Walleye Capital's CYTK Position: Q1 2026 in Review

Walleye Capital sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 15,131 shares — an estimated $962K sold.

Walleye Capital first reported a position in CYTK in Q2 2019 and held it in 13 quarters. The position peaked at $9.81M in Q4 2022. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Walleye Capital reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 15,131 Cytokinetics shares in Q1 2026, an estimated $962K.
  • Walleye Capital first reported a position in Cytokinetics in Q2 2019 and held it in 13 quarters.
  • Walleye Capital's Cytokinetics position peaked at $9.81M in Q4 2022.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.